Joinn Laboratories(China)Co.Ltd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Joinn Laboratories(China)Co.Ltd yıllık ortalama 10.2% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 17.2% annual. Gelirler yılda ortalama 26% oranında büyüyor .

Anahtar bilgiler

10.2%

Kazanç büyüme oranı

7.1%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	26.8%
Gelir büyüme oranı	26.0%
Özkaynak getirisi	-0.1%
Net Marj	-0.04%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Joinn Laboratories(China)Co.Ltd nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

XSSC:603127 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	2,125	-1	332	90
30 Jun 24	2,214	137	323	88
31 Mar 24	2,332	-63	313	92
31 Dec 23	2,376	397	315	97
30 Sep 23	2,579	770	311	106
30 Jun 23	2,503	794	316	109
31 Mar 23	2,366	1,137	324	93
31 Dec 22	2,268	1,074	310	78
30 Sep 22	1,936	941	316	63
30 Jun 22	1,759	775	297	51
31 Mar 22	1,587	589	270	50
31 Dec 21	1,517	557	273	48
30 Sep 21	1,301	419	278	37
30 Jun 21	1,213	379	261	44
31 Mar 21	1,122	389	243	49
31 Dec 20	1,076	315	219	51
30 Sep 20	922	253	182	62
30 Jun 20	836	237	159	52
31 Mar 20	720	194	138	44
31 Dec 19	639	187	113	40
30 Sep 19	513	128	106	32
30 Jun 19	475	126	97	29
31 Mar 19	432	112	91	25
31 Dec 18	409	108	85	24
30 Sep 18	375	99	76	25
30 Jun 18	341	87	57	36
31 Mar 18	334	92	56	31
31 Dec 17	301	76	59	26
30 Sep 17	294	74	59	19
31 Dec 16	242	52	66	0
31 Dec 15	207	49	56	0
31 Dec 14	185	49	45	0
31 Dec 13	144	22	43	0

Kaliteli Kazançlar: 603127 şu anda kârlı değil.

Büyüyen Kar Marjı: 603127 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 603127 kârlı değildir, ancak son 5 yılda zararlarını yılda 10.2% oranında azaltmıştır.

Büyüme Hızlandırma: 603127 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 603127 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( -14.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 603127 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -0.11% ) sahiptir.

Joinn Laboratories(China)Co.Ltd Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.32 in 3Q 2023)

Joinn Laboratories(China)Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.13 loss in 2Q 2023)

Joinn Laboratories(China)Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

First quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.25 profit in 1Q 2023)

Joinn Laboratories(China)Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.32 in 3Q 2023)

Joinn Laboratories(China)Co.,Ltd. Announces Resignation of Yao Dalin as Executive Director and Vice General Manager

Joinn Laboratories(China)Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.13 loss in 2Q 2023)

Dividend of CN¥0.16 announced

Joinn Laboratories(China)Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

First quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.25 profit in 1Q 2023)

Joinn Laboratories(China)Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.53 (vs CN¥1.44 in FY 2022)

Joinn Laboratories(China)Co.,Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 30 August 2024

Investor sentiment improves as stock rises 19%

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 19%

Now 23% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Now 20% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

GM, Secretary to the Board recently sold CN¥2.5m worth of stock

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.35 in 3Q 2022)

New minor risk - Share price stability

Co-Founder & Vice Chairman recently sold CN¥6.2m worth of stock

Vice GM & Executive Director recently sold CN¥6.9m worth of stock

Second quarter 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.33 profit in 2Q 2022)

Now 25% undervalued after recent price drop

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥12m worth of stock

Co-Founder & Vice Chairman recently sold CN¥8.9m worth of stock

Joinn Laboratories (China) Co.,Ltd. Declares Final Dividend for the Year Ended December 31, 2022, Payable on 20 July 2023

Joinn Laboratories(China)Co.,Ltd., Annual General Meeting, Jun 09, 2023

First quarter 2023 earnings released: EPS: CN¥0.35 (vs CN¥0.24 in 1Q 2022)

Insider recently sold CN¥56m worth of stock

JOINN Laboratories (China) Co., Ltd. Provides Revenue Guidance for the Period January 1, 2022 to December 31, 2022

Insider recently sold CN¥57m worth of stock

Co-Founder & Vice Chairman recently sold CN¥31m worth of stock

Insider recently sold CN¥30m worth of stock

Co-Founder & Vice Chairman recently sold CN¥65m worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.18 in 3Q 2021)

Now 21% undervalued after recent price drop

Co-Founder & Vice Chairman recently sold CN¥180m worth of stock

Insider recently sold CN¥60m worth of stock

Now 20% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: CN¥0.46 (vs CN¥0.11 in 2Q 2021)

Joinn Laboratories(China)Co.,Ltd. SHS (China) to Be Deleted from OTC Equity

Joinn Laboratories(China)Co.,Ltd. to Report Q2, 2022 Results on Aug 30, 2022

Joinn Laboratories(China)Co.,Ltd. Provides Earnings Guidance for the Period from 1 January 2022 to 30 June 2022

Senior Vice GM recently sold CN¥233k worth of stock

Joinn Laboratories(China)Co.,Ltd. Approves Final Dividend in Cash for the Year Ended December 31, 2021, Payable on 23 August 2022

Investor sentiment deteriorated over the past week

Vice GM & Executive Director recently sold CN¥4.6m worth of stock

Founder & Chairman recently sold CN¥51m worth of stock

Investor sentiment improved over the past week

Joinn Laboratories (China) Co.,Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021, Payable on 23 August 2022

Founder & Chairman recently sold CN¥36m worth of stock

First quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.28 in 1Q 2021)

Less than half of directors are independent

Joinn Laboratories (China) Co.,Ltd. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings released: EPS: CN¥1.51 (vs CN¥0.99 in FY 2020)

Joinn Laboratories (China) Co.,Ltd. Proposes Final Cash Dividend for the Year Ended December 31, 2021

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Joinn Laboratories (China) Co.,Ltd. Provides Unaudited Earnings Guidance for the Year Ended December 31, 2021

Insider recently sold CN¥23m worth of stock

Insider recently sold CN¥23m worth of stock

Third quarter 2021 earnings released: EPS CN¥1.43 (vs CN¥0.13 in 3Q 2020)

Insider recently sold CN¥99m worth of stock